Immunometabolic Regulation of Vaccine-Induced Antibody Responses in Aging Mice.

Immunometabolic Regulation of Vaccine-Induced Antibody Responses in Aging Mice.

Publication date: Aug 26, 2024

Immune cells undergo metabolic reprogramming to meet the demands associated with immune responses. The effects of aging on these pathways and on the metabolic phenotype of the immune cells participating in antibody responses to vaccines are still largely unknown. Here we used a vaccine for SARS-CoV-2 that utilizes the cellular heat shock chaperone glycoprotein 96 (gp96), engineered to co-express SARS-CoV-2 Spike (spike) protein (gp96-Ig-S). Results show that this vaccine induces comparable B cell primary responses in young and old mice at later time points, but a significantly lesser secondary response in old as compared to young mice, with the antibodies generated in the secondary response being also of lower avidity. This occurs because aging changes the B cell metabolic phenotype and induces hyper-metabolic B cells that are associated with higher intrinsic inflammation and decreased protective antibody responses. However, the gp96-Ig-S vaccine was found to be effective in significantly reducing the metabolic/inflammatory status of B cells from old mice, suggesting the possibility that targeting metabolic pathways may improve immune function in old mice that do not respond adequately to the vaccine.

Open Access PDF

Concepts Keywords
Aging B cells
Basel immunometabolism
Gp96 inflammation
Immunometabolic vaccine
Mice

Semantics

Type Source Name
disease MESH shock
disease IDO protein
disease IDO cell
disease MESH inflammation
pathway KEGG Metabolic pathways
drug DRUGBANK Efavirenz
disease MESH infections
drug DRUGBANK Indoleacetic acid
disease MESH abnormalities
disease MESH insulin sensitivity
disease IDO blood
pathway REACTOME Fatty acids
pathway KEGG Oxidative phosphorylation
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Coenzyme M
pathway REACTOME Immune System
disease IDO pathogen
disease MESH tumor
disease IDO facility
disease IDO reagent
drug DRUGBANK Abacavir
disease IDO assay
drug DRUGBANK Biotin
drug DRUGBANK Urea
drug DRUGBANK Oxygen
drug DRUGBANK L-Glutamine
drug DRUGBANK Rotenone
drug DRUGBANK Pidolic Acid
pathway REACTOME Glycolysis
drug DRUGBANK Methyl isocyanate
disease MESH respiratory tract infections
disease MESH COVID 19 pandemic
disease IDO role
drug DRUGBANK Etoperidone
pathway KEGG Insulin resistance
disease MESH Oxidative damage
disease IDO susceptibility
drug DRUGBANK Serine
drug DRUGBANK Palmitic Acid
disease MESH obesity
disease MESH infectious diseases
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH Autoimmunity
pathway REACTOME Metabolism
disease MESH influenza
disease IDO infection

Original Article

(Visited 5 times, 1 visits today)